Multivariable analysis incorporating number of ctDNA mutations out of 6 significant genes, clinical factors, and plasma DNA concentration
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . | ctRRMM-PI score . |
|---|---|---|---|---|---|---|
| No. of ctDNA mutations, n ≥ 2 | 1.2 | 3.5 | 2.0 | 6.0 | 1.0 × 10−5 | 2 |
| Number of ctDNA mutations, n = 1 | 0.8 | 2.2 | 1.3 | 3.6 | .0025 | 1 |
| No. of prior regimens, n ≥ 3 | 0.9 | 2.4 | 1.4 | 4.2 | .0015 | 2 |
| No. of prior regimens, n = 2 | 0.4 | 1.5 | 0.8 | 2.8 | .16 | 0 |
| Plasma DNA concentration: high | 0.5 | 1.7 | 1.1 | 2.6 | .020 | 1 |
| Variable . | Coefficient . | HR . | 95% lower CI . | 95% upper CI . | P value . | ctRRMM-PI score . |
|---|---|---|---|---|---|---|
| No. of ctDNA mutations, n ≥ 2 | 1.2 | 3.5 | 2.0 | 6.0 | 1.0 × 10−5 | 2 |
| Number of ctDNA mutations, n = 1 | 0.8 | 2.2 | 1.3 | 3.6 | .0025 | 1 |
| No. of prior regimens, n ≥ 3 | 0.9 | 2.4 | 1.4 | 4.2 | .0015 | 2 |
| No. of prior regimens, n = 2 | 0.4 | 1.5 | 0.8 | 2.8 | .16 | 0 |
| Plasma DNA concentration: high | 0.5 | 1.7 | 1.1 | 2.6 | .020 | 1 |
HRs for PFS evaluated by Cox PH model incorporating the total number of ctDNA mutations in the 6 prognostically significant genes, clinical factors (treatment indication and number of prior therapies), and plasma DNA concentration in 161 RRMM cases analyzed by both ctDNA-seq and BMPC-seq.
High and low plasma DNA concentration by a median split. Final Cox PH model after stepwise variable selection minimizing Akaike’s information criterion are shown.